Literature DB >> 14526389

Life and death decisions by E2F-1.

L A Bell1, K M Ryan.   

Abstract

Deregulation of the transcription factor E2F-1 is a common event in most human cancers. Paradoxically, E2F-1 has been shown to have the ability to induce both cell cycle progression and programmed cell death, leading potentially to both tumour-promoting as well as tumour-suppressive effects. Although the pathway to cell cycle progression seems straightforward with a number of growth-promoting E2F target genes having been described, the pathways to apoptosis are less well defined and more complex. The discovery that E2F-1 'knockout' mice are highly tumour prone has caused a recent surge in the number of reports relating to programmed cell death. This review focuses on these recent findings, highlighting the way in which they have increased our understanding of E2F-1-induced cell death, as well as indicating the questions that remain. Insight gained as to the role of this intriguing molecule in cancer and its potential for targeted therapy will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14526389     DOI: 10.1038/sj.cdd.4401324

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  50 in total

1.  Deregulation of Rb-E2F1 axis causes chromosomal instability by engaging the transactivation function of Cdc20-anaphase-promoting complex/cyclosome.

Authors:  Somsubhra Nath; Abhishek Chowdhury; Sanjib Dey; Anirban Roychoudhury; Abira Ganguly; Dibyendu Bhattacharyya; Susanta Roychoudhury
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

Review 2.  The role of RAD9 in tumorigenesis.

Authors:  Howard B Lieberman; Joshua D Bernstock; Constantinos G Broustas; Kevin M Hopkins; Corinne Leloup; Aiping Zhu
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

3.  Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis.

Authors:  Piyali Dasgupta; Jiazhi Sun; Sheng Wang; Gina Fusaro; Vicki Betts; Jaya Padmanabhan; Saïd M Sebti; Srikumar P Chellappan
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

4.  Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.

Authors:  Khanh H Nguyen; Paul Hachem; Li-Yan Khor; Naji Salem; Kelly K Hunt; Peter R Calkins; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

5.  A computational genomics approach to identify cis-regulatory modules from chromatin immunoprecipitation microarray data--a case study using E2F1.

Authors:  Victor X Jin; Alina Rabinovich; Sharon L Squazzo; Roland Green; Peggy J Farnham
Journal:  Genome Res       Date:  2006-10-19       Impact factor: 9.043

6.  EAPP, a novel E2F binding protein that modulates E2F-dependent transcription.

Authors:  Michael Novy; Regina Pohn; Peter Andorfer; Tina Novy-Weiland; Barbara Galos; Ludwig Schwarzmayr; Hans Rotheneder
Journal:  Mol Biol Cell       Date:  2005-02-16       Impact factor: 4.138

7.  Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue.

Authors:  Brian J Albert; Ananthapadmanabhan Sivaramakrishnan; Tadaatsu Naka; Nancy L Czaicki; Kazunori Koide
Journal:  J Am Chem Soc       Date:  2007-02-06       Impact factor: 15.419

8.  Lentivirus-mediated RNA interference targeting E2F-1 inhibits human gastric cancer MGC-803 cell growth in vivo.

Authors:  Xiao Tong Wang; Yu Bo Xie; Qiang Xiao
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

9.  Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells.

Authors:  Xiao-Ming Shuai; Gao-Xiong Han; Guo-Bin Wang; Jun-Hua Chen
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

10.  E2F1 regulates the base excision repair gene XRCC1 and promotes DNA repair.

Authors:  Dexi Chen; Zhiyong Yu; Zhiyi Zhu; Charles D Lopez
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.